Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target at $81.50

Key Points

• Ultragenyx Pharmaceutical Inc. has received a consensus recommendation of "Moderate Buy" from twelve brokerages, with eleven analysts rating it as a buy.
• The stock showed a 0.5% increase recently and is currently trading at approximately $29.52, significantly below its 52-week high of $60.37.
• In its last quarterly earnings report, Ultragenyx beat analysts' expectations with a revenue of $166.50 million, up 13.2% year-over-year, despite reporting a negative EPS of ($1.17).

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $81.50.

RARE has been the subject of several research reports. Wedbush lowered their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research report on Monday, July 14th. William Blair initiated coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 price target for the company. Cantor Fitzgerald lowered their price target on shares of Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating for the company in a research report on Wednesday, August 6th. HC Wainwright raised shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price target for the company in a research report on Monday, July 28th. Finally, Wells Fargo & Company lowered their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research report on Thursday, July 10th.

Insider Activity at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the transaction, the director owned 15,344 shares in the company, valued at $573,712.16. The trade was a 13.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Deep Track Capital LP bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $27,493,000. First Light Asset Management LLC increased its stake in Ultragenyx Pharmaceutical by 1.1% during the 4th quarter. First Light Asset Management LLC now owns 763,607 shares of the biopharmaceutical company's stock valued at $32,125,000 after purchasing an additional 8,505 shares in the last quarter. Dark Forest Capital Management LP acquired a new position in Ultragenyx Pharmaceutical during the 4th quarter valued at approximately $459,000. Stifel Financial Corp increased its stake in Ultragenyx Pharmaceutical by 13.5% during the 4th quarter. Stifel Financial Corp now owns 23,796 shares of the biopharmaceutical company's stock valued at $1,001,000 after purchasing an additional 2,835 shares in the last quarter. Finally, Alyeska Investment Group L.P. increased its stake in Ultragenyx Pharmaceutical by 23.1% during the 4th quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock valued at $60,570,000 after purchasing an additional 269,733 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Trading Up 1.8%

Shares of RARE stock traded up $0.52 during trading hours on Friday, reaching $30.08. 1,153,951 shares of the stock were exchanged, compared to its average volume of 1,614,092. Ultragenyx Pharmaceutical has a 12-month low of $25.81 and a 12-month high of $60.37. The company's 50-day moving average price is $31.25 and its 200-day moving average price is $35.46. The firm has a market capitalization of $2.90 billion, a price-to-earnings ratio of -5.44 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.10. The company had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm's quarterly revenue was up 13.2% on a year-over-year basis. During the same period in the previous year, the company earned ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.